Trials / Completed
CompletedNCT00467012
Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy, safety, and pharmacokinetics when R435 and paclitaxel are administered concomitantly to patients with metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bevacizumab | 10mg/kg，Day1, 15 of 1 cycle(4 weeks) |
| DRUG | Paclitaxel | 90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks) |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2009-06-01
- Completion
- 2011-09-01
- First posted
- 2007-04-27
- Last updated
- 2012-04-26
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00467012. Inclusion in this directory is not an endorsement.